Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief Medical Officer | September 06, 2022 | September 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date September 06, 2022 · Filed September 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2032-09-06 | Direct | 100,000 |
Reported balance
After 2022-09-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-06 · Grant · Acquired 100,000 · Balance 100,000 F1: Granted as an inducement equity award under the Aquestive Therapeutics, Inc. 2022 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5636(c)(4). The options will vest annually 25% on the first and second anniversaries of the Grant Date and 50% on the third anniversary of the Grant Date, subject to Dr. Truitt's continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted as an inducement equity award under the Aquestive Therapeutics, Inc. 2022 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5636(c)(4). The options will vest annually 25% on the first and second anniversaries of the Grant Date and 50% on the third anniversary of the Grant Date, subject to Dr. Truitt's continued employment through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2022 Filed Sep 8, 2022 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001214659-22-010993 · marketforms-57083.xml · derivative · entry 1 Truitt Kenneth · CIK 0001946056 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-06 F1 · derivative.exercise_date: Granted as an inducement equity award under the Aquestive Therapeutics, Inc. 2022 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5636(c)(4). The options will vest annually 25% on the first and second anniversaries of the Grant Date and 50% on the third anniversary of the Grant Date, subject to Dr. Truitt's continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.